Yeah that’s not the case literally thousands of western owned drugs are available in the chinese market and even companies such as Tesla service the region - you don’t carve out 10% of the market - you do exactly as we have done fine a reputable partner who knows their market.
interestingly James himself believes this deal values us for further deals at around 1B that’s pretty much x8 on the closing price of last week...
I particularly like words to this effect...
we are well funded, we are well taken care of in China, we have secured two great licensing deals in a month, we still hold the big opportunity in hand and ‘we don’t need to do anything’...
IMHO these deals has put us on the radar for licensing deals now - and we are in the enviable position of being cashed up and able to enter discussions holding all the cards and with a massive body of data flowing through potential partners will be constantly reminded of the opportunity here.
- Forums
- ASX - By Stock
- KZA
- Ann: Kazia licenses paxalisib to Simcere in Greater China
Ann: Kazia licenses paxalisib to Simcere in Greater China, page-53
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online